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Aim To update the estimate of multiple sclerosis (MS) prev-
alence in Croatia using multiple epidemiological tools.
Methods This level IV, epidemiological study gathered 
data from three national patient registries and one data-
base of a non-governmental MS patients’ organization. 
Data were extracted on all individuals who had undergone 
hospital MS treatment, consulted their primary health care 
providers about MS-related symptoms, been listed as hav-
ing MS-related disability, or been members of the men-
tioned non-governmental organization in 2015. A new 
database was formed, in which all living individuals were 
identified using a common identification number to pre-
vent double entries. The prevalence rates in 2015 were cal-
culated by age and sex groups.
Results In total, 6160 patients diagnosed with MS were 
identified (72% women). Most women with MS were 50-59 
years old and most men were 40-49 years old. The overall 
MS prevalence rate was 143.8 per 100 000 population.
Conclusion The calculated MS prevalence rate in Croatia 
in 2015 was more than twice as high as the estimate from 
2013. This difference warrants further research into MS epi-
demiology in Croatia and calls for a rational allocation of 
funds and human resources to provide adequate care and 
support to MS patients.
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It is difficult to compare multiple sclerosis (MS) incidence 
and prevalence rates among European countries owing to 
a lack of epidemiological studies addressing the issue. This 
has impeded burden of disease assessment and compara-
tive research into the care costs of MS patients (1). The Mul-
tiple Sclerosis International Federation published the Atlas 
of Multiple Sclerosis (Atlas of MS) in collaboration with the 
World Health Organization (WHO) in 2008 (2) and inde-
pendently in 2013 (3). These epidemiological publications 
have facilitated the comparison of epidemiological data 
across different countries, helping to develop public poli-
cies and services for improving the life quality of MS pa-
tients. According to the Atlas of MS, the average worldwide 
MS prevalence was 30 per 100 000 population in 2008 and 
33 per 100 000 population in 2013. The rates were repro-
duced from peer-reviewed articles of local or national epi-
demiological studies, where possible. Elsewhere, they were 
taken from local or national patient registries or articles not 
published in peer-reviewed journals. Regional variations in 
MS incidence and prevalence based on such reports were 
significant; some authors ascribe such an unequal distribu-
tion to genetic differences, environmental factors (eg, cli-
mate), or their interaction (4).
Both Atlas of MS editions list Croatia among the countries 
with an above-average MS prevalence rate of 60-100 and 
20-60 per 100 000 population in 2008 and 2013, respec-
tively. The latter figure implies that patients with MS living 
in Croatia would number 2500 at most. Moreover, these 
figures imply that MS prevalence in Croatia decreased in 
the period 2008-2013, although at that time there were no 
considerable advances in early detection, diagnostic pro-
cedures, treatment, and rehabilitative measures.
In order to better assess the actual MS prevalence in Croa-
tia, we decided to conduct a new study based on data from 
multiple data sources aggregated in the Croatian Institute 
of Public Health (CIPH). Per Official Statistical Records Act 
and the Program of Statistical Activities for the period 
2013-2017, CIPH is the national focal point for aggregation 
of data on health care indicators and their statistical analy-
sis (5,6). In accordance with the WHO recommendations, 
divisions within the CIPH collect data on recorded disease 
or disorder cases and related health care measures. How-
ever, the number of patients obtained in this way may not 
represent the overall number of patients with a particular 
disease, as some patients may choose not to seek health 
care during a particular time period (eg, when their dis-
ease is in remission) or may only seek assistance from 
a single health care provider (eg, a general practitio-
ner). Recent advances in anonymization techniques have 
allowed for unambiguous linking of data contained in all 
CIPH patient registries and databases. These include the 
Disabled Persons Registry (ROI), containing information an 
all Croatian citizens diagnosed with professional disabil-
ity, and the In-patient Statistics Form (BSO) database, con-
taining information on all stationary medical treatments 
registered in Croatia. Moreover, since 2015 CIPH has been 
granted the access to the data on primary health care pro-
vider services contained in the Central Health Information 
System of Croatia (CEZIH). Linking these sources allows for 
the determination of a more accurate number of MS pa-
tients, rather than just the pattern of health care services 
they use.
There have been no previous studies on the MS prevalence 
of in Croatia using CIPH data. Materljan and Sepčić (7) as-
sessed regional MS prevalence in Croatia, but did not cal-
culate the overall prevalence rate. Moreover, the data they 
used were largely based on historical reports. The aim of 
this study was to determine the number of patients cur-
rently diagnosed with MS in Croatia, based on data con-
tained in available registries. The hypothesis of this study 
was that the number of MS patients in Croatia thus deter-
mined would differ significantly from the estimations pub-
lished in Atlas of MS editions.
MeTHoDS
This level IV, epidemiological study included the following 
data sources:
1) The database containing information on all medical ser-
vices provided by primary health care providers in Croatia 
in 2015 (CEZIH)
2) The database containing information on all patients who 
underwent hospital treatment in Croatia in 2015 (BSO)
3) The Disabled Persons Registry (ROI) of the CIPH
4) The database containing information on all members 
of the Alliance of Croatian Multiple Sclerosis Associations 
(SDMSH).
All of the sources listed individuals’ age, sex, residence, 
and the personal identification number (OIB), serving as a 
unique identifier. Additionally, the CEZIH database includ-
ed the International Statistical Classification of Diseases 
and Related Health Problems (ICD) code attributed to the 
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patient on his or her visit, information about prescribed 
drugs and referrals, whereas the BSO database included 
data on the duration of hospital treatment and the asso-
ciated ICD code. The ROI registry contained information 
about the extent and cause of the disability (as coded in 
ICD). The SDMSH database contained no additional infor-
mation except the demographic data and OIB identifier; 
in order to acquire SDMSH membership, applicants had 
to provide a physician’s certificate attesting MS had been 
diagnosed.
The data analysis was conducted during March and 
April 2017 in the Division for Public Health of the CIPH. 
The data were extracted on all individuals who had un-
dergone hospital treatment for MS (BSO database), con-
sulted their primary health care providers for MS-related 
symptoms (CEZIH database), been listed as having an MS-
related disability in the ROI registry, or been members of 
SDMSH. The inclusion criterion was diagnosed MS, as per 
the ICD code G35; however, we were not able to evalu-
ate whether every person with the ICD code G35 met the 
diagnostic criteria for MS, such as McDonald criteria (8). 
Deceased patients and patients with residence outside 
Croatia (verified using the national health insurance reg-
istry) were excluded from the study.
The data in the tables were extracted from BSO, CEZIH, ROI, 
and SDMSH databases using SQL Server Management Stu-
dio 2012 software (Microsoft, Redmond, WA, USA) and ana-
lyzed using Microsoft Excel 2010. All individuals were iden-
tified using their OIB number, preventing double entries. 
Some previous studies have used similar methodology 
and Eurostat has stated that this method allows for more 
accurate data collection on MS incidence (9). The study 
was approved by the CIPH Ethics Committee on March 1, 
2017, under the registration number 381-03-351-17-3.
ReSulTS
There were 6160 MS patients; 4394 (72%) were women 
(women-to-men ratio: 2.49) (Table 1). Most women with MS 
(n = 1105) were in the age group 50-59, whereas most men 
(n = 480) were in the age group 40-49. The overall MS preva-
lence rate in Croatia was 143.8 patients per 100 000 popu-
lation. The distribution of prevalence rates by age groups 
was unimodal and roughly normal, with the greatest preva-
TaBle 1. Patients diagnosed with multiple sclerosis in Croatia by sex and age groups
Male population Female population Total population
age group patients PR* patients PR patients PR
0-9    0   0.0    1   0.5    1   0.2
10-19   14   5.7   23   9.8   37   7.7
20-29  125  44.5  320 118.6  445  80.8
30-39  415 141.2  856 299.9 1271 219.4
40-49  480 162.1 1052 352.5 1532 257.7
50-59  370 118.7 1105 344.7 1475 233.3
60-69  256 117.9  758 294.3 1014 213.6
70-79   86  55.4  227  97.6  313  80.7
80 +   20  38.9   52  44.4   72  42.7
Total 1766  85.5 4394 198.1 6160 143.8
*PR – prevalence rate per 100 000 population.
†Data on the number of inhabitants in particular sex and age groups (2011 Census) were retrieved from the Croatian Bureau of Statistics web-site 
(10).




in the respective 
database
Proportion of 
total number (%) 
of MS patients 
(N = 6160)
Number of 
MS patients listed 
only in respective 
database
Proportion (%) of 
MS patients listed only in 
the respective database 
(N = 6160)
Central Health Information System of Croatia 5106 82.9 863 14.0
In-patient Statistics Form database 2966 48.1 187  3.0
Disabled Persons Registry 2962 48.1 285  4.6
Alliance of Croatian Multiple Sclerosis 
Associations
2665 43.2 100  1.6
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lence rate in the age group 40-49 for both sexes. There was 
a single MS case in the age group 0-9 (an eight-year old fe-
male patient), whereas 72 cases were recorded in the age 
group over 80; the oldest patient was aged 96 years.
The greatest proportion of MS patients was included in the 
CEZIH database, accounting for 82.9% of the total number 
of MS patients; less than 50% was included in other data 
sources (Table 2). In addition, the CEZIH database includ-
ed 863 patients not listed in any of the other data sourc-
es (14.0% of the total number of MS patients); the respec-
tive numbers in other databases were considerably lower. 
There was a considerable overlap between the data sourc-
es, especially with regard to the CEZIH database (Table 3).
DISCuSSIoN
The total number of MS patients in Croatia determined in 
this study exceeds manifold the estimations in the 2008 
and 2013 Atlas of MS editions. Considering the derived MS 
prevalence rate, Croatia groups among the countries with 
the highest disease prevalence (prevalence rate higher than 
100 per 100 000 population). This group includes the United 
States, Canada, the United Kingdom, and the Scandinavian 
countries (3,11). A number of previous studies purported 
there was an MS prevalence south-north gradient, with the 
highest rates in Northern European population; however, 
the study by Wade and the results of our study suggest 
there are other pathogenetic factors that should be tak-
en into consideration (12).
Planning and policy design in the health care system, key 
to achieving optimal outcomes in patient care, should be 
based on accurate information (13). Had resource plan-
ning and allocation in Croatia been done based on the 
Atlas of MS data, erroneous conclusions and inadequate 
health care provision would have been inevitable. During 
the preparation of both Atlas editions, the data-gathering 
coordinators for Croatia were SDMSH members and their 
associates. They derived the required MS epidemiology 
indicators from the SDMSH member registry: more spe-
cifically, the number of SDMSH members was used as the 
approximate number of MS patients in Croatia. However, 
membership in SDMSH is purely voluntary; the necessary 
prerequisites are the clinically confirmed MS diagnosis (ICD 
code: G35) and an established residency in Croatia. Our re-
sults show that many MS patients were not included in the 
SDMSH registry, and that other data sources, CEZIH in par-
ticular, allow for more exact estimates to be made.
Although data from four different sources were used and 
cross-linked in this study, allowing for greater accuracy, it is 
possible that the prevalence of MS in Croatia may be even 
higher, because not all patients may have sought medical 
assistance for MS in national health care institutions during 
2015, nor were all MS patients obliged to be members of 
SDMSH. Moreover, there is a possibility that in some situa-
tions the ICD code G35 may have been misattributed.
The United Kingdom National Institute for Health and Care 
Excellence (NICE) recommends that the period between 
TaBle 3. Number of multiple sclerosis (MS) patients in Croatia included in multiple data sources*
Number of databases
Number of MS patients 
included in listed databases
Proportion (%) of MS patients 
included in listed databases (N = 6160)
Two databases*
CEZIH + BSO 1135 18.4
CEZIH + ROI  467  7.6
CEZIH + SDMSH  247  4.0
BSO + ROI   34  0.6
BSO + SDMSH   27  0.4
ROI + SDMSH  180  2.9
Three databases
CEZIH + BSO + ROI  321  5.2
CEZIH + BSO + SDMSH  436  7.1
CEZIH + ROI + SDMSH  849 13.8
BSO + ROI + SDMSH   38  0.6
Four databases
CEZIH + BSO + ROI + SDMSH  788 12.8
*CeZIH – Central Health Information System of Croatia; BSo – In-patient Statistics Form database; RoI – Disabled Persons Registry; SDMSH – alliance 
of Croatian Multiple Sclerosis associations.
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the onset of MS symptoms and the first neurological refer-
ral examination should not exceed six weeks (14). Also, the 
period between the first examination and completion of 
all diagnostic tests should not exceed six-weeks. Accord-
ing to the 2013 study, only 61.5% of patients diagnosed 
with MS in Croatia were referred to a neurologist within 
six weeks from the symptoms’ onset, whereas only 64.1% 
were diagnosed with MS during the following six weeks 
(15). The discrepancy between the current practice in Cro-
atia and the NICE recommendations might be caused by 
a lack of neurologists and other necessary personnel in-
volved in neurological care, as the number of patients far 
exceeded the one expected, in addition to limited financial 
and material resources. The failure to meet the NICE rec-
ommendations (for over a third of all patients) is unsurpris-
ing if we take into consideration that previous health care 
provision plans had been based on the estimate of 2500 
MS patients living in Croatia.
However, the main reason why our results could significant-
ly influence MS patients’ medical care is that an early referral 
to specialized MS center can improve outcomes (16), since 
early referral leads to earlier diagnosis and earlier treatment. 
With the changing landscape of treatment options for MS 
and available therapies that can alter the disease course, 
the knowledge about the scope of the problem will enable 
health care authorities to better plan resources needed for 
appropriate management of MS patients.
Regarding direct expenses of care in the United States, MS 
ranks as the second most costly chronic disease (behind 
congestive heart failure) (17). It is reasonable to assume 
that treatment costs and burden of disease grow as the pa-
tient’s disability progresses. However, recent studies from 
the United States warn of a lack of current data on the ef-
fect of MS-related disability on treatment expenses (18,19). 
In Croatia, there are no systems comprehensively monitor-
ing medical expenses related to particular medical entities, 
including MS. Considering the current health care system 
reform proposals, the data presented in this research may 
help in future planning and allocation of financial health 
care resources for MS patients in Croatia.
The study’s limitation are the possible errors in the use of 
ICD code G35, designating MS in BSO and CEZIH databas-
es. The database used in this study was formed by aggre-
gating data entries from different databases, rather than 
by directly examining patient histories. However, the influ-
ence of misattribution errors is likely to be small and could 
not have significantly altered the results. Data entries ex-
tracted from the ROI and SDMSH databases were attested 
for by medical records.
The current MS prevalence rate in Croatia is 143.8 patients 
per 100 000 population, greatly exceeding previously pub-
lished formal estimates. By linking anonymized data ex-
tracted from multiple databases we determined a revised 
prevalence rate, which may help health care providers in 
Croatia to amend plans on resource allocation and better 
conform to NICE MS guidelines. To further improve epide-
miological assessments and consequent resource plan-
ning, it would be beneficial to establish a national regis-
try of MS patients. Furthermore, BSO and CEZIH databases 
contain some additional information not analyzed in this 
study. It may be useful to analyze these data and present 
them to the decision makers. Conducting similar studies to 
determine the prevalence of other common diseases may 
also be of benefit.
acknowledgment The authors thank Ivan Pristaš, Borna Pleše, and Srđan 
Golubović for their assistance in retrieving the necessary data in CIPH da-
tabases; and Prof Slava Podobnik Šarkanji, Željka Antunović, and Tanja 
Malbaša for their support and helpful information during the study plan-
ning process.
Funding None.
ethical approval received from the CIPH Ethics Committee on March 1, 
2017, under the registration number 381-03-351-17-3.
Declaration of authorship TB and DR designed the study. TB, VŠ, ŽD, IC, DR, 
SM, and RS acquired the data. TB, VŠ, ŽD, IC, MH, SM, and RS analyzed the 
data. TB, VŠ, ŽD, IC, DR, MH, and RS critically revised the manuscript for im-
portant intellectual content. All authors took part in drafting of the manu-
script, gave final approval, and agreed to be accountable for all aspects of 
the work. 
Competing interests All authors have completed the Unified Competing 
Interest form at www.icmje.org/coi_disclosure.pdf (available on request 
from the corresponding author) and declare: no support from any organi-
zation for the submitted work; no financial relationships with any organiza-
tions that might have an interest in the submitted work in the previous 3 
years; no other relationships or activities that could appear to have influ-
enced the submitted work.
References
1 Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei l, 
et al. The epidemiology of multiple sclerosis in europe. eur J 
Neurol. 2006;13:700-22. Medline:16834700 doi:10.1111/j.1468-
1331.2006.01342.x
2 World Health organization and Multiple Sclerosis International 
Federation. atlas: Multiple Sclerosis Resources in the World 2008. 
Healthline. available from: http://www.who.int/mental_health/
neurology/atlas_MS_WeB.pdf. accessed: February 17, 2017.
3 Multiple Sclerosis International Federation. atlas of MS 2013. 
available from: http://www.atlasofms.org/. 2013. accessed: 
February 17, 2017.
4 Koch-Henriksen N, Sřrensen PS. The changing demographic 
pattern of multiple sclerosis epidemiology. lancet Neurol. 




5 official Statistics act of the Republic of Croatia [in Croatian]. official 
Gazette of the Republic of Croatia, 103/03, 75/09, 59/12, 12/13.
6 Croatian Bureau of Statistics. Program of Statistical activities 
of the Republic of Croatia 2013-2017 [in Croatian]. Zagreb, 
2013. available from: https://www.dzs.hr/hrv/about_us/legals/
Program%20statistickih%20aktivnosti%202013-2017.pdf. 
accessed: april 19 2018.
7 Materljan e, Sepčić J. epidemiology of multiple sclerosis in Croatia. 
Clin Neurol Neurosurg. 2002;104:192-8. Medline:12127653 
doi:10.1016/S0303-8467(02)00037-9
8 National Multiple Sclerosis Society. updated McDonald criteria 
expected to speed the diagnosis of MS and reduce misdiagnosis. 




accessed: april 30, 2018.
9 eurostat. Morbidity statistics methodology pilot studies – 




multiple_sclerosis. accessed: april 19, 2017.
10 Croatian Bureau of Statistics. Census 2011: Population By Single 
age and Sex, By Counties. Microsoft excel table. available from: 
http://www.dzs.hr/Hrv/censuses/census2011/results/xls/Zup_01_
HR.xls. accessed: april 19, 2018.
11 Kingwell e, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow 
Sa. Incidence and prevalence of multiple sclerosis in europe: a 
systematic review. BMC Neurol. 2013;13:128. Medline:24070256 
doi:10.1186/1471-2377-13-128
12 Wade BJ. Spatial analysis of global prevalence of multiple sclerosis 
suggests need for an updated prevalence scale. Mult Scler Int. 
2014;2014:124578. Medline:24693432
13 Hogan WR, Wagner MM. accuracy of data in computer-based 
patient records. J am Med Inform assoc. 1997;4:342-55. 
Medline:9292840 doi:10.1136/jamia.1997.0040342
14 National Institute for Health and Care excellence. Multiple sclerosis 
in adults: management, Clinical guideline [CG186]. 2014. available 
from: https://www.nice.org.uk/guidance/CG186/chapter/1-
Recommendations#diagnosing-ms-2. accessed on april 19 2018.
15 adamec I, Barun B, Gabelić T, Zadro I, Habek M. Delay in the 
diagnosis of multiple sclerosis in Croatia. Clin Neurol Neurosurg. 
2013;115 Suppl 1:S70-2. Medline:24321160 doi:10.1016/j.
clineuro.2013.09.025
16 Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, 
Pepper G, et al. Brain health: time matters in multiple sclerosis. 
Mult Scler Relat Disord. 2016;Suppl 1:S5-48. Medline:27640924 
doi:10.1016/j.msard.2016.07.003
17 adelman G, Rane SG, Villa CF. The cost burden of multiple sclerosis 
in the united States: a systematic review of the literature. J Med 
econ. 2013;16:639-47. Medline:23425293 doi:10.3111/13696998.20
13.778268
18 Jones e, Pike J, Marshall T, Ye X. Quantifying the relationship 
between increased disability and health care resource utilization, 
quality of life, work productivity, health care costs in patients with 
multiple sclerosis in the uS. BMC Health Serv Res. 2016;16:294. 
Medline:27443278 doi:10.1186/s12913-016-1532-1
19 ernstsson o, Gyllensten H, alexanderson K, Tinghög P, Friberg 
e, Norlund a. Cost of illness of multiple sclerosis – a systematic 
review. PloS one. 2016;11:e0159129. Medline:27411042 
doi:10.1371/journal.pone.0159129
